BPC-157 has been evaluated in cellular and animal-based research models to assess its effects
on tissue-response signaling, vascular activity, and physiological recovery pathways.
Key investigations examine its interaction with growth-related signaling mechanisms,
collagen-associated processes, and inflammatory mediators under controlled experimental
conditions. Additional studies continue to explore its possible relevance in tendon,
ligament, muscle, and gastrointestinal research models.
Price range: $50.00 through $90.00
Every serious peptide company prominently displays this. Example Research Use Only All products offered by Dakota Peptology are intended strictly for laboratory research purposes.
Every serious peptide company prominently displays this. Example Research Use Only All products offered by TruPeptides are intended strictly for laboratory research purposes.
BPC-157 is a synthetic peptide sequence derived from the bovine stomach fund (BPC), intended for academic and scientific research applications. This molecule has been studied in preclinical research for its potential biological properties, including tissue repair and regeneration mechanisms, which remain under investigation within laboratory settings.
BPC-157 is part of a broader class of peptides known as Bioactive Polypeptides, initially isolated from bovine gastric juice. Since its discovery, this peptide has been investigated primarily in animal models and in vitro studies to explore its potential effects on wound healing, gastrointestinal repair, and tissue regeneration. The research focus has largely centered on its mechanisms of action at the cellular and molecular level, rather than therapeutic efficacy in humans.
Preclinical studies involving BPC-157 have demonstrated its potential to modulate inflammatory responses, stimulate cellular proliferation, and enhance extracellular matrix production in various tissues. These findings are typically observed in controlled experimental environments, such as laboratory animals with induced injuries or degenerative conditions. Importantly, while early results suggest promising biological activity, translation of these findings to human health remains speculative and is not supported by any approved clinical applications as of the latest available scientific data.
The information provided regarding BPC-157 is for academic and scientific research purposes only. This peptide is not intended for human or animal consumption, nor does it constitute medical advice. All research involving BPC-157 must adhere to ethical standards, regulatory guidelines, and institutional approvals applicable to the institution conducting the study. Further investigation is required before any conclusions can be drawn regarding potential therapeutic or biological effects in vivo. Researchers are advised to consult relevant literature and local regulatory authorities for up-to-date guidelines.
For research use only. Not for human or animal consumption.
Gastric pentadecapeptide BPC 157 is a naturally derived peptide found in gastric juice, known for its exceptional stability in acidic environments. It remains intact for over 24 hours, allowing oral administration without degradation.
Prior studies have demonstrated its ability to accelerate healing of muscles, tendons, ligaments, and bone tissue. It has been shown to restore myotendinous junctions and support recovery in severe musculoskeletal injuries that typically do not regenerate.
This study evaluated whether stable gastric pentadecapeptide BPC 157 could reverse permanent quadriceps muscle-to-bone detachment in rats.
The goal was to assess whether oral administration could achieve both functional and structural recovery—an outcome not previously achieved with pharmacological interventions.
Male Wistar rats underwent surgical detachment of the quadriceps muscle from the femur and iliac bone. Treatment groups received BPC 157 orally at doses of 10 µg/kg or 10 ng/kg, starting five minutes post-surgery.
Recovery was monitored over 90 days using walking recovery indices, motor function testing, biomechanical assessments, MRI and ultrasound imaging, and histological analysis.
Rats treated with BPC 157 showed significant recovery in walking ability and motor function, achieving near-normal gait patterns. In contrast, untreated controls exhibited persistent impairment.
Muscle contracture was completely reversed in treated animals, while untreated rats developed progressive atrophy. Imaging confirmed closure of the muscle–bone gap within weeks, and full reattachment was observed by day 90.
Ultrasound imaging demonstrated early closure of the detachment gap within 21–28 days. MRI scans confirmed complete reattachment at 90 days in treated animals.
Histological analysis revealed integration of muscle fibers into newly formed bone, organized collagen deposition, and reactivation of periosteal tissue—indicating true structural regeneration.
BPC 157 promoted mesenchymal cell proliferation and periosteal activation, enabling new bone formation and muscle integration.
Additional mechanisms included angiogenesis (enhanced blood supply), cytoprotection (reduced tissue damage), and modulation of the nitric oxide (NO) pathway, which supports vascular regulation and tissue repair.
These findings suggest that BPC 157 may play a significant role in treating severe musculoskeletal injuries, including tendon ruptures, ligament damage, and bone repair scenarios.
Its oral stability and broad regenerative profile distinguish it from traditional therapies that degrade rapidly or lack multi-system healing effects.
BPC 157 successfully achieved complete muscle-to-bone reattachment in rat models, restoring both function and structural integrity.
Treated animals demonstrated full recovery, while untreated controls showed permanent impairment. These results strongly support further translational research into its role in musculoskeletal repair.
